Bevacizumab-Induced Hypothyroidism: A Case Study

October 2024 in “ Journal of the Endocrine Society ”

Amanda L. McKenna, Sanjana Thota-Kammili, Krista Grennan, Sarika Rao

New to Vascular Endothelial Growth Factor? There is a guide in the encyclopedia. Read the guide →

bevacizumab VEGF thyroid dysfunction levothyroxine TSH hair loss

Studysummary In this case report, researchers observed that the monoclonal antibody bevacizumab may worsen hypothyroidism in patients, as seen in a 60-year-old woman with metastatic duodenal carcinoma. The authors suggest that thyroid function should be monitored when using VEGF inhibitor therapies due to potential adverse effects.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer ·

View this study on academic.oup.com →

Discuss this study in the Community →

Similar Research

5 / 1000+ results

research O-21 FROM ORAL LEVOTHYROXINE RESISTANCE TO INTRAVENOUS LEVOTHYROXINE HYPERSENSITIVITY: A CHALLENGING PRIMARY HYPOTHYROIDISM CASE

January 2026 in “JCEM Case Reports”

The researchers reported a case of a 51-year-old woman with primary hypothyroidism who developed anaphylaxis to intravenous levothyroxine after being unresponsive to oral formulations, highlighting potential allergic reactions to IV treatments in such patients.

research ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy

November 2022 in “Journal of the Endocrine Society”

This case study reports that immunotherapy with ipilimumab and nivolumab induced hypophysitis in a patient with renal cell carcinoma, emphasizing the need for careful monitoring of endocrine function in such treatments.

research Vandetanib-associated alopecia areata in a patient with metastatic medullary thyroid cancer

1 citations , July 2014 in “International Journal of Dermatology”

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

research Absence of chemotherapy-induced alopecia with paclitaxel in a case of hypothyroidism: case report

3 citations , October 2003 in “Annals of Oncology”

This case study reported a rare and delayed onset of alopecia in a patient after paclitaxel chemotherapy, potentially influenced by the interaction of thyroid hormones and chemotherapy affecting hair follicle cycles.

research Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea

39 citations , June 2019 in “Frontiers in Endocrinology”

This study reported that while both sorafenib and lenvatinib may require dose modifications due to adverse events in treating advanced or metastatic thyroid cancers, key differences in side effect profiles were observed.